Monitoring pharmacokinetics of anticancer drugs: Non-invasive investigation using magnetic resonance spectroscopy

Advanced Drug Delivery Reviews

Volumn 41, Issue 1, 2000, Pages 75-89

  Griffiths, John R ^a   Glickson, Jerry D ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anticancer drugs; Magnetic resonance spectroscopy; Pharmacodynamics; Pharmacokinetics

Indexed keywords

MAGNETIC RESONANCE SPECTROSCOPY; METABOLISM; METABOLITES; ONCOLOGY;

ANTICANCER DRUGS;

PHARMACOKINETICS;

1 (1,1,1,3,3,3 HEXAFLUORO 2 PROPOXY) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2 (2 NITRO 1 IMIDAZOLYL) N (3,3,3 TRIFLUORO 2 HYDROXYPROPYL)ACETAMIDE; 3 AMINOBENZAMIDE; 6 O BENZYLGUANINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BETA,BETA DIFLUOROCHLORAMBUCIL; CARBON 13; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; EDOXUDINE; FLOXURIDINE; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IPROPLATIN; MISONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; RADIOSENSITIZING AGENT; TEGAFUR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG MONITORING; DRUG RETENTION; DRUG TISSUE LEVEL; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVIEW;

EID: 0033995074     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00057-5     Document Type: Article

References (67)

1. Robinson S.P., McCoy C.L., Griffiths J.R. Animal tumor models. Grant D.M., Harris R.K. Encyclopedia of Nuclear Magnetic Resonance. Vol. 2:1996;828-833 Wiley, New York.
2. Negendank W. Studies of human tumours by MRS: a review. NMR Biomed. 5:1992;303-324.
3. Glickson J.D. Cells and cell systems. Grant D.M., Harris R.K. Encyclopedia of Nuclear Magnetic Resonance. Vol. 2:1996;1209-1217 Wiley, New York.
4. Baluch S., Mildwood C.J., Griffiths J.R., Stubbs M., Coombes R.C. Monitoring therapeutic response to tamoxifen in NMU induced rat mammary tumours by 31P MRS. Br. J. Cancer. 63:1991;901-904.
5. He Q., Bhujwalla Z.M., Maxwell R.J., Griffiths J.R., Glickson J.D. Proton observation of the antineoplastic agent iproplatin in vivo by selective multiple quantum coherence transfer (Sel-MQC). Magn. Reson. Med. 33:1995;414-416.
6. Evelhoch J.L., McCoy C.L., Giri B.P. A method for direct in vivo measurement of drug concentrations from a single 2H NMR spectrum. Magn. Reson. Med. 9:1989;402-410.
7. 13C glucose metabolism in tumors by heteronuclear cross-polarization. Magn. Reson. Med. 33:1995;151-155.
8. 19F NMR. Br. J. Cancer. 50:1984;113-117.
9. McSheehy P.M.J., Lemaire L.P., Griffiths J.R. Fluorine-19 MRS: application in oncology. Grant D.M., Harris R.K. Encyclopedia of Nuclear Magnetic Resonance. Vol. 2:1996;2048-2052 Wiley, New York.
10. 31P-MRS in rat tumours: increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas. Br. J. Cancer. 75:1997;62-68.
11. Payne G.S., Pinkerton C.R., Leach M.O. Studies of ifosfamide in vivo: observation and optimization. Proc. Int. Soc. Magn. Reson. Med. 7:1999;1588.
12. Becker M., Port R.E., Zabel H.-J., Zeller W.J., Bachert P. Monitoring local disposition kinetics of carboplatin in vivo after subcutaneous injection in rats by means of 195Pt NMR. J. Magn. Reson. 133:1998;115-122.
13. Bachert P. Pharmacokinetics using fluorine NMR in vivo. Prog. Nucl. Magn. Reson. Spectrosc. 33:1998;1-56.
14. Presant C.A., Wolf W., Waluch V., Wiseman C., Kennedy P., Blayney D., Brechner R.R. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet. 343:1994;1184-1187.
15. 19F-MRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed. 11:1998;380-387.
16. 19F-NMR spectroscopy. J. Cancer Res. Clin. Oncol. 117:1991;295-304.
17. 19F MRS studies of fluoropyrimidine chemotherapy. A review. NMR Biomed. 2:1989;133-141.
18. Prior M.J.W., Maxwell R.J., Griffiths J.R. Fluorine-19 NMR spectroscopy and imaging in vivo. NMR Basic Principles & Progress. 28:1992;102-130.
19. 19F-MRS study in vivo. Br. J. Cancer. 65:1992;369-375.
20. 31P magnetic resonance spectroscopy. Eur. J. Cancer. 33:1997;2418-2427.
21. Brix G., Bellemann M.E., Gerlach L., Haberkorn U. Biochemical modulation of the anticancer drug 5-fluorouracil by bromovinyluracil: assessment by metabolic imaging. Proc. Int. Soc. Magn. Reson. Med. 7:1999;1355.
22. McSheehy P.M.J., Kralavonsky J., Jeney A., Pandi E., Katona C., Noordhuis P., Peters G.F., Rodrigues L.M., Griffiths J.R. Investigations of modulation of 5-fluorouracil (FU) pharmacokinetics by 5-ethyl-2′-deoxyuridine (EUdR) in tumor-bearing mice and rats. Proc. Int. Soc. Magn. Reson. Med. 7:1999;1354.
23. 19F NMR study. Cancer Chemother. Pharmacol. 42:1998;341-344.
24. McSheehy P.M.J., Robinson S.P., Ujugo A.S.E., Aboagye E.O., Cannell M.B., Leach M.O., Judson I.R., Griffiths J.R. Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo. Cancer Res. 58:1998;1185-1194.
25. Rowland I.J., Maxwell R.J., Baluch S., Ujugo A.S.E., Griffiths J.R., Leach M.O. Identifying the cellular location of metabolites in vivo using paramagnetically enhanced spectroscopy. Proc. Soc. Magn. Reson. 2:1994;390.
26. 19F MRS method. Proc. Soc. Magn. Reson. 3:1995;1689.
27. Brix G., Bellemann M.E., Gerlach L., Haberkorn U. Intra- and extracellular fluorouracil uptake: assessment with contrast-enhanced metabolic F-19 imaging. Radiology. 209:1998;259-267.
28. Hu X., Levin D.N., Lauterbur P.C., Spraggins T. SLIM: spectral localization by imaging. Magn. Reson. Med. 8:1988;314-322.
29. Loffler R., Sauter R., Kolem H.A.H., von Kienlin M. Localized spectroscopy from anatomical matched compartments: improved sensitivity and localization for cardiac 31P MRS in humans. J. Magn. Reson. 134:1998;287-299.
30. 19F NMR spectroscopy of the antimetabolites 5-fluorouracil and its analogues: an assessment of drug metabolism. Biochem. Pharmacol. 39:1990;857-863.
31. 19F magnetic resonance spectroscopy in vivo. Int. J. Radiat. Oncol. Biol. Phys. 16:1988;925-929.
32. Aboagye E.O., Maxwell R.J., Kelson A.B., Tracy M., Lewis A.D., Graham M.A., Horsman M.R., Griffiths J.R., Workman P. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetabmide (SR-4554) as a probe for the measurement of tumor hypoxia. Cancer Res. 57:1997;3314-3318.
33. Bellemann M.E., Schlicker A., Mier W., Peschke P., Brix G. Biodistribution and pharmacokinetics of the radiosensitizer 3-aminobenzamide: assessment with fluorine-19 NMR imaging. Proc. Int. Soc. Magn. Reson. Med. 7:1999;1353.
34. Bellemann M.E., Haberkorn U., Gerlach L., Blatter J., Brix G. Imaging of the biodistribution and metabolization of the antineoplastic agent gemcitabine in tumor-bearing rats. Proc. Int. Soc. Magn. Reson. Med. 7:1999;1352.
35. Workman P., Maxwell R.J., Griffiths J.R. Non-invasive MRS in new anticancer drug development. NMR Biomed. 5:1992;270-272.
36. 19F NMR spectroscopy. Br. J. Cancer. 62:1990;766-772.
37. 19F nuclear magnetic resonance imaging of drug distribution in vivo: the disposition of an antifolate anticancer drug in mice. Magn. Reson. Med. 17:1991;189-196.
38. 31P MRS studies of ifosfamide in vivo: observation and optimisation. Proc. Int. Soc. Magn. Reson. Med. 7:1999;1588.
39. Newlands E.S., Blackledge G.R.P., Slack J.A., Rustin G.J.S., Smith D.B., Stuart N.S.A., Quarterman C.P., Hoffman R., Stevens J.F.G., Brampton M.H., Gibson A.C. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer. 65:1992;287-291.
40. Newlands E.S., Stevens M.F., Wedge S.R., Wheelhouse R.T., Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev. 23:1997;35-61.
41. Denny B.J., Wheelhouse R.T., Stevens M.F., Tsang L.L., Slack J.A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry. 33:1994;9045-9051.
42. Newlands E.S., O'Reilly S.M., Glaser M.G., Bower M., Evans H., Brock C., Brampton M.H., Colquhoun I., Lewis P., Rice-Edwards J.M., Illingworth R.D., Richards P.G. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur. J. Cancer. 32A:1996;2236-2241.
43. Bower M., Newlands E.S., Bleehen N.M., Brada M., Begent R.J.H., Calvert H., Colquhoun I., Lewis P., Brampton M.H. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high grade glioma. Cancer Chemother. Pharmacol. 40:1997;484-488.
44. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br. J. Cancer. 67:1993;1299-1302.
45. 15N) magnetic resonance investigation of temozolomide and mitozolomide. J. Chem. Soc., Perkin Trans. 00:1995;249-252.
46. Meikle S.R., Matthews J.C., Brock C.S., Wells P., Harte R.J.A., Cunningham V.J., Jones T., Price P. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother. Pharmacol. 42:1998;183-193.
47. Ernst R.R., Bodenhausen G., Wokaun A. Principles of Nuclear Magnetic Resonance in One and Two Dimensions. 1987;467-469 Clarendon Press, Oxford.
48. Freeman R.A. Handbook of Nuclear Magnetic Resonance. 1988;Longman Scientific & Technical, Essex, UK. pp. 218.
49. Morris G.A., Freeman R. Enhancement of nuclear magnetic resonance signals by polarization transfer. J. Am. Chem. Soc. 101:1979;760-762.
50. Doddrell D.M., Pegg D.T., Bendall M.R. Distortionless enhancement of NMR signals by polarization transfer. J. Magn. Reson. 48:1982;323-327.
51. Freeman R., Mareci T., Morris G.A. Weak satellite signals in high-resolution NMR spectra: separating the wheat from the chaff. J. Magn. Reson. 42:1981;341-345.
52. 13C nuclei only. J. Am. Chem. Soc. 103:1981;934-936.
53. 13C}-1H resonances in the in vivo NMR spectrum. J. Magn. Reson. 71:1987;532-538.
54. van Zijl P.C.M., Chesnick A.S., DesPres D., Moonen C.T.W., Ruiz-Cabello J., van Gelderer P. In vivo proton spectroscopy and spectroscopic imaging of [1-13C]glucose and its metabolic products. Magn. Reson. Med. 30:1993;544-551.
55. 13C-decouple spectroscopic measurements of lactate and glutamate in the rat brain in vivo. Proc. Natl. Acad. Sci. USA. 82:1985;1633-1637.
56. 13C NMR spectroscopy. Soc. Magn. Reson. Abstr. 1:1995;524.
57. 13C labelled anticancer agent temozolomide detected in vivo by selective cross polarization transfer. Magn. Reson. Med. 34:1995;338-342.
58. Kety S.S. The theory and applications of the exchange of inert gas at the lungs and tissues. Pharmacol. Rev. 3:1951;1-41.
59. Stevens M.F., Hickman J.A., Langdon S.P., Chubb D., Vickers L., Stone R., Baig G., Goddard C., Gibson N.W., Slack J.A., Newton C., Lunt E., Fizames C., Lavelle F. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazole[5,1-d]-1,2,3,5-tetrazin-4(3H-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 47:1987;5846-5852.
60. Tozer G.M., Lewis S., Michalowski A., Aber V. The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br. J. Cancer. 61:1990;250-257.
61. Evelhoch J.L. Measurement of tumor blood flow by deuterium NMR and the effects of modifiers. NMR Biomed. 5:1992;290-295.
62. Griffiths J.R. Are cancer cells acidic? Br. J. Cancer. 64:1991;425-427.
63. 13C glucose in tumors. Third International Conference on Magnetic Resonance Microscopy, Heidelberg Conference, Abstracts :1995;109.
64. He Q., Bhujwalla Z.M., Glickson J.D. Proton NMR detection of multiple metabolites in tissues containing mobile lipid by spin echo enhanced selective multiple quantum coherence transfer with application to EMT6 tumors. J. Magn. Reson. B. 112:1996;18-25.
65. Ordidge R.J., Connelly A., Lohman J.A.B. Image-selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J. Magn. Reson. 66:1986;283-294.
66. Ordidge R.J., Halpern J.A., Qing Z.X., Knight R.A., Nagesh V. Correction of motional artifacts in diffusion weighted MR imaging using navigator echos. Magn. Reson. Imaging. 12:1994;455-460.
67. Perera A., Jackson H., Sharma H.L., McAuliffe C.A., Fox B.W. A comparative binding of platinum anti-tumor compounds to plasma proteins in the rat (in vivo) and mouse (in vitro). Chem.-Biol. Interact. 85:1992;199-213.